BIIB and SAGE Related Headlines
Go Back- Biogen (BIIB) and Sage (SAGE) Announce ZURZUVAE Now Available in the U.S.
- ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
- Stifel Downgrades Sage Therapeutics (SAGE) to Hold, 'we think Biogen is unlikely to buy Sage outright '
- Sage, Biogen receive setback despite FDA approval of postpartum depression drug. This is why
- SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD
- FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
BIIB and SAGE Related Press Releases
Go Back- ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
- FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
